Abstract
New macrolides, such as clarithromycin and azithromycin, are active agents to Mycobacterium avium complex (MAC). Both clarithromycin and azithromycin are well-known for the ability to improve the prognosis of AIDS patients with disseminated MAC infection. However, the administration of monotherapy with a macrolide is usually associated with the emergence of drug resistance after a few months of use. Therefore, the recommended treatment for MAC infection involved the use of at least two antibiotics, which includes a macrolide in combination with rifabutin, moxifloxacin and / or ethambutol. When used as prophylactic therapy in AIDS patients, azithromycin is more convenient (1200 mg, once a week) than clarithromycin (500 mg, twice a day). Ketolides are a semi-synthetic derivative of erythromycin A, which differs from erythromycin A by substitution of a 3- keto group for L-cladinose. Telithromycin has a carbamate group linked to an imidazolium and pyridium nucleus at C11- C12. In mice model, both telithromycin and ABT-733 were active in vivo against MAC.
Keywords: macrolides, clarithromycin, azithromycin, roxithromycin
Current Pharmaceutical Design
Title: Effects of Macrolides and Ketolides on Mycobacterial Infections
Volume: 10 Issue: 26
Author(s): Luiz E. Bermudez and Yoshitaka Yamazaki
Affiliation:
Keywords: macrolides, clarithromycin, azithromycin, roxithromycin
Abstract: New macrolides, such as clarithromycin and azithromycin, are active agents to Mycobacterium avium complex (MAC). Both clarithromycin and azithromycin are well-known for the ability to improve the prognosis of AIDS patients with disseminated MAC infection. However, the administration of monotherapy with a macrolide is usually associated with the emergence of drug resistance after a few months of use. Therefore, the recommended treatment for MAC infection involved the use of at least two antibiotics, which includes a macrolide in combination with rifabutin, moxifloxacin and / or ethambutol. When used as prophylactic therapy in AIDS patients, azithromycin is more convenient (1200 mg, once a week) than clarithromycin (500 mg, twice a day). Ketolides are a semi-synthetic derivative of erythromycin A, which differs from erythromycin A by substitution of a 3- keto group for L-cladinose. Telithromycin has a carbamate group linked to an imidazolium and pyridium nucleus at C11- C12. In mice model, both telithromycin and ABT-733 were active in vivo against MAC.
Export Options
About this article
Cite this article as:
Bermudez E. Luiz and Yamazaki Yoshitaka, Effects of Macrolides and Ketolides on Mycobacterial Infections, Current Pharmaceutical Design 2004; 10 (26) . https://dx.doi.org/10.2174/1381612043383241
DOI https://dx.doi.org/10.2174/1381612043383241 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Label-Free Mass Spectrometry-Based Plasma Proteomics Identified LY6D, DSC3, CDSN, SERPINB12, and SLURP1 as Novel Protein Biomarkers For Pulmonary Tuberculosis
Current Proteomics Ureas: Applications in Drug Design
Current Medicinal Chemistry Characterizing the Binding of Angiotensin Converting Enzyme I Inhibitory Peptide to Human Hemoglobin: Influence of Electromagnetic Fields
Protein & Peptide Letters Hybrid Molecules Development: A Versatile Landscape for the Control of Antifungal Drug Resistance: A Review
Mini-Reviews in Medicinal Chemistry Preparation and Characterization of A Nanoliposomal Vaccine of pcLACK Candidate Against Cutaneous Leishmaniasis
Infectious Disorders - Drug Targets Current Bioactive Azole-Containing Natural Products
Current Bioactive Compounds Nanostructured Therapeutic Carriers for Tuberculosis Treatment: Approaches & Challenges
Recent Patents on Anti-Infective Drug Discovery Antimicrobial Potentials, Phytochemical Screening and Determination of Bioactive Compounds from Three Indian Folk Medicinal Plants
Current Bioactive Compounds Extrapulmonary Tuberculosis- Its Management and Control
Current Drug Therapy Innate Immunity and Primary Biliary Cirrhosis
Current Molecular Medicine P2X Receptors and Inflammation
Current Medicinal Chemistry Editorial [ Infectious Disorders Drug Targets - An Arsenal of Knowledge on Pathogen Targets ]
Infectious Disorders - Drug Targets Antimicrobial Peptides: A Promising Therapeutic Strategy in Tackling Antimicrobial Resistance
Current Medicinal Chemistry Adverse Drug Reactions in a Pulmonary Teaching Hospital: Incidence, Pattern, Seriousness, and Preventability
Current Drug Safety Vitamins in the Prevention or Delay of Cognitive Disability of Aging
Current Aging Science Functions of Antimicrobial Peptides in Vertebrates
Current Protein & Peptide Science Antimicrobial Activities of 1-H-Benzimidazole-based Molecules
Current Topics in Medicinal Chemistry The Role and Potential Therapeutical Applications of Antimicrobial Proteins in Infectious and Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Antigen Discovery for Serological Diagnosis of Visceral Leishmaniasis
Current Chemical Biology Chronic Stress and Diabetes Mellitus: Interwoven Pathologies
Current Diabetes Reviews